Press Releases


Therapeutic Solutions International Recruits NFL Chargers Hall of Famer Wes Chandler to Lead NeuroStilbene for Chronic Traumatic Encephalopathy in Football Players

Company to Advance NeuroStilbene Product for High-Performance Athletes Susceptible to Head Injuries

OCEANSIDE, Calif., Aug. 22, 2018 (GLOBE NEWSWIRE) — via OTC PR WIRE — Therapeutics Solutions International, Inc., (OTC Markets: TSOI) announced today recruitment of Wes Chandler to lead the development of its NeuroStilbene product for use in patients at risk of developing chronic traumatic encephalopathy (CTE).

Wes Chandler was a wide receiver in the National Football League (NFL) for eleven seasons during the 1970s and 1980s. He was selected to the Pro Bowl four times and ranked twelfth in NFL history in receiving yards and thirteenth in receptions when he retired. Chandler is a member of the San Diego Chargers Hall of Fame. He played college football for the Florida Gators and was also inducted into the College Football Hall of Fame in 2015.

CTE is caused by repetitive concussive/sub-concussive hits to the head sustained over a period of years and is often found in football players. The condition is characterized by memory loss, impulsive/erratic behavior, impaired judgment, aggression, depression, and dementia. In many patients with CTE, it is anatomically characterized by brain atrophy, reduced mass of frontal and temporal cortices, and medial temporal lobe.

At a molecular level, it is known that CTE is associated with chronic activation of a cell type in the brain called the “microglia[1]”. Studies have shown that pterostilbene, the active ingredient in NeuroStilbene, is capable of decreasing microglial activation, as well as reducing neuroinflammation, one of the major causes of CTE[2].

“I have witnessed firsthand the devastation caused by CTE. I am very excited to work with TSOI at developing NeuroStilbene as an over the counter spray that is available for all athletes before exposure to activities where the risk of brain injury/concussions exists,” stated Wes Chandler.

“We are very excited to work with Wes and the numerous colleagues and relations he has developed over the decades in professional sports, in order to provide solutions that not only prevent the onset of CTE but also in some cases reversing it,” said James Veltmeyer, MD, Chief Medical Officer of the Company.

“The formal launching of the CTE Program at TSOI is an indication of the breadth of different therapeutic indications that the pterostilbene molecule is capable of addressing,” said Timothy Dixon, President, and CEO of the Company. “Given that NeuroStilbene is generated from ingredients that are Generally Regarded as Safe, the Company is capable of initiating sales of this product immediately, with confidence the market demand exists. We look forward to working with Wes and preventing and hopefully reversing this terrible condition.”

About Therapeutic Solutions International, Inc.
Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. Immune modulation refers to the ability to upregulate (make more active) or downregulate (make less active) one’s immune system. The Company’s corporate website is

1 Blaylock et al. Surg Neurol Int. 2011; 2: 107.

2 Huo et al. Prog Neuropsychopharmacol Biol Psychiatry. 2014 Oct 3;54:92-102.

Safe Harbor Statement

This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like “may,” “will,” “should,” “could,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” or “project” or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our SEC filings. To the extent that statements in this press release are not strictly historical, including statements as to product launch timing, revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future collaboration agreements, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.


Therapeutic Solutions International, Inc.